Table 2.

Univariable analysis of progression-free survival.

Predictors	Hazard ratio	95% CI		P value
		Lower	Upper
TMT median
> 6.24 mm vs. ≤ 6.24 mm	0.358	0.195	0.658	0.0001*
cT category
T2 vs. T1	0.968	0.357	2.624	0.948
T3 vs. T1	1.776	0.663	4.756	0.252
T4 vs. T1	2.666	1.037	6.855	0.041*
cN category
N1 vs. N0	1.138	0.4967	2.607	0.76
N2 vs. N0	2.406	1.171	4.947	0.017*
N3 vs. N0	5.185	2.196	12.24	0.0001*
cM category
M1 vs. M0	6.164	2.47	15.38	0.0001*
Overall stage
II vs. I	1.031	0.3226	3.294	0.959
III vs. I	1.583	0.5682	4.409	0.38
IV vs. I	3.68	1.3897	9.742	0.009*
Age (years)	1.019	0.995	1.044	0.121
Sex
Men vs. women	0.8239	0.4074	1.666	0.59
Smoking status
Former vs. never	0.9747	0.489	1.943	0.942
Current vs. never	1.085	0.5412	2.173	0.819
Initial surgery
Yes vs. no	0.728	0.403	1.317	0.294
Surgery after neoadjuvant chemoradiation
Yes vs. no	1.38	0.544	3.502	0.498
Adjuvant radiation or chemoradiation
Yes vs. No	2.463	0.763	7.957	0.132
Human papillomavirus
Positive vs. negative	0.895	0.4517	1.773	0.75
Tumor site
Oral cavity vs. sinonasal cavity	0.7416	0.186	2.958	0.672
Nasopharynx vs. sinonasal cavity	0.9071	0.224	3.673	0.891
Oropharynx vs. sinonasal cavity	1.2354	0.356	4.286	0.739
hypopharynx vs. sinonasal cavity	1.298	0.321	5.251	0.715
Larynx vs. sinonasal cavity	1.6772	0.472	5.96	0.424
Preoperative serum albumin level	0.8352	0.483	1.444	0.519

CI confidence interval, TMT temporalis muscle thickness, cT clinical tumor, cN clinical node, cM clinical metastasis.

*P value less than 0.05 indicates statistical significance.